Ajanta Pharma Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/eoma47zjeilgawzz4jksetw1.pdf

Key Takeaways


US Generics: The Inspection Gate

Yogesh Agrawal: "We have some good products, unfortunately the approvals were lost, now hopefully the inspection starts, so yes we have some good products, which we have already filed and there are some good products which are at advanced stage of filing during the current year also. So they all can bring good value to the company."

Branded Generics: Asia & Africa

Yogesh Agrawal: "All our brand generic business in the exports also they are all driven by us. So we decide the product, we decide the price, we decide the promotion. Distributor just distributes the product for a cost. So we are able to decide our course of growth, so that is where the beauty is."

India Business: Strong Quarter, Normalizing Ahead


Margin Walk & Cost Headwinds

Yogesh Agrawal: "I think the industry has understood that this is not helping in fact it is hurting all the companies."

Pipeline, Capex & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
India branded business growthMid-teens growth for FY23FY23
Asia and Africa branded generics growthMid-teens growth for both regionsFY23
US generics growth (without new launches)Flattish to low-single-digit, roughly 4–6%FY23
US ANDA filings10–12 filings, pace picking up from Q2FY23
EBITDA margin25–26% rangeFY23
Raw material costClose to 26% going forwardFrom Q2 FY23 onward
R&D spend~6% of revenueFY23
Tax rate~21% for FY23, 20–21% next yearFY23 and FY24
Capex~Rs. 200 Crores including maintenanceFY23
US price erosionNormalizing to 5–8% rangeOngoing
Four US products awaiting inspectionLaunch in Q3 if inspection happens, Q4 if delayed by a quarterH2 FY23, conditional on FDA inspection

Key Metrics

MetricQ1 FY23
Total consolidated revenue₹951 cr, +27% YoY
EBITDA₹222 cr, margin at 23% vs 29% YoY
PAT₹175 cr, +1% YoY; PAT margin at 18%
Raw material cost29% of revenue, vs guidance of 25–26%; includes 2% one-time inventory write-off
R&D expenses₹54 cr, 6% of revenue
Other income₹33 cr, including forex gain of ₹28 cr
Income tax rate21%, expected to remain at similar level for FY23
Capex incurred₹43 cr; full-year FY23 estimate ~₹200 cr
India branded generic sales₹279 cr, +22% YoY; 30% of total revenue
India growth breakup7% price increase, 6% volume growth, 3% new product launches
India trade generic sales₹33 cr, vs ₹27 cr in Q1 FY22
Asia branded generic sales₹240 cr, +45% YoY
Africa branded generic sales₹168 cr, +34% YoY
Asia and Africa branded generic exports₹408 cr, +41% YoY; 43% of total revenue
US generic sales₹179 cr, +6% YoY; 19% of total revenue
African institution sales₹77 cr, +44% YoY; 8% of total revenue
US ANDAs awaiting approval20 as of end of June 2022; aiming to file 10–12 in FY23
India IQVIA ranking28 in June 2022, improved from 29 in March 2022
NLEM portfolio share of India business~12%
Field force size growth~8% YoY
EBITDA margin guidance for FY2325–26%
India business growth guidance for FY23Mid-teens
Asia and Africa branded generic business growth guidanceMid-teens
US business growth expectation without new launchesFlattish to low single digit, maybe 5–6% for FY23
US price erosion last year15–18%
Export freight cost8% of revenue, vs ~6% pre-COVID; ~₹14 cr adverse impact in the quarter